CD4 and cancer: In contrast, treatment with the known anticancer agent FR901228 (VanderMolen et al., 2011) induced Annexin V staining of all the cancer cells tested (Figs. 4A–4C) as well as activated CD4 T-cells, but not in naïve CD4 T-cells (Fig. 5).